文献速递妇科产科

晚期子宫癌新辅助化疗的应用与结局

Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer.
PubMed 文献 · Gynecol Oncol · 2021-06-20

该研究利用SEER-Medicare数据库分析2000至2015年3037例IV期子宫癌患者,比较新辅助化疗(NACT)与初次肿瘤细胞减灭术(PCS)的使用趋势、围手术期结局和生存。NACT使用率从9.5%升至29.2%,两组在同时接受化疗和手术的患者中癌症特异性和总生存无差异,NACT组内科并发症更少。

要点

  • IV期子宫癌中NACT使用率从9.5%增至29.2%。
  • NACT与PCS在化疗加手术患者中生存无差异。
  • NACT组内科并发症发生率低于PCS组(28.9% vs 39.4%)。

核心结论

  • 对于IV期子宫癌,NACT使用增加,且与PCS相比生存无差异,内科并发症更少。

研究设计与样本

  • 回顾性队列研究,使用SEER-Medicare数据库纳入2000至2015年3037例IV期子宫癌女性。

主要发现

  • 1629例(53.6%)接受PCS,554例(18.2%)接受NACT,854例(28.1%)未治疗。
  • NACT使用率从9.5%上升至29.2%。
  • NACT组28.6%行间歇性子宫切除术,PCS组64.6%接受化疗。
  • NACT组广泛细胞减灭术比例71.7%,低于PCS组的79.1%(P=0.03)。
  • 并发症率NACT组52.8% vs PCS组56.2%(P=0.42);内科并发症PCS组39.4% vs NACT组28.9%(P=0.01)。

临床怎么用

  • IV期子宫癌可考虑NACT作为PCS的替代方案,尤其关注减少内科并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Neoadjuvant chemotherapy (NACT) has emerged as an alternative to primary cytoreductive surgery (PCS) for stage IV uterine cancer. We examined utilization, perioperative outcomes and survival for NACT and PCS for stage IV uterine cancer. METHODS: The Surveillance, Epidemiology, End Results-Medicare database was used to identify women with stage IV uterine cancer treated from 2000 to 2015. Women were classified as NACT or PCS. Interval cytoreductive surgery (after NACT) or chemotherapy (after PCS) were recorded. The extent of surgery and perioperative outcomes were estimated for the groups. Multivariable proportional hazards models and Kaplan-Meier analyses were used to examine survival. RESULTS: Among 3037 women, 1629 (53.6%) were treated with primary cytoreductive surgery, 554 (18.2%) with NACT, and 854 (28.1%) received no treatment. Use of NACT increased from 9.5% to 29.2%. After NACT, interval hysterectomy was performed in 159 (28.6%), while within the PCS group, 1052 (64.6%) received chemotherapy. Extended cytoreductive procedures were performed in 71.7% of women who received NACT vs. 79.1% after PCS (P = 0.03). The complication rate was 52.8% for NACT versus 56.2% for PCS (P = 0.42); medical complications were more frequently seen in the PCS group (39.4% versus 28.9%; P = 0.01). There was no difference in cancer specific (P = 0.48) or overall survival (P = 0.25) in women who received both chemotherapy and surgery regardless of whether the initial treatment was NACT or PCS. CONCLUSION: Use of NACT is increasing for advanced stage uterine cancer. There was no difference in survival between NACT and primary cytoreductive surgery and NACT was associated with fewer perioperative medical complications.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wright JD, Huang Y, Melamed A, et al. Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. Gynecol Oncol. 2021. PMID: 34158181. doi:10.1016/j.ygyno.2021.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。